About CLINUVEL

About CLINUVEL

Experts in light and skinClinuvel's logo

CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders. With its unique expertise in understanding the interaction of light and human skin, the company has identified patient populations with a clinical need for photoprotection and another population with a need for repigmentation. These patient groups range in size from 5,000 to 45 million.

CLINUVEL’s lead product, SCENESSE® (afamelanotide 16mg), a first-in-class drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the US and Europe, and has been granted marketing authorisation by the European Commission for adults with EPP. Based in Melbourne, Australia, CLINUVEL has operations in Europe, the US and Singapore.

 

Latest Company Announcements

10 January 2018

Chair Letter to Shareholders

Whilst the Board of CLINUVEL looks back on a very successful 2017 it must now look forward to exciting times ahead.

Read More
21 December 2017

CLINUVEL Newsletter - December 2017

In the last communiqué of the calendar year, we take a breath and contemplate CLINUVEL’s status, a holding position for our teams over Christmas in the run up to a full 2018.

Read More
20 December 2017

Preliminary recommendation by NICE not to include SCENESSE® for reimbursement by NHS England

CLINUVEL PHARMACEUTICALS LTD today announced that the first draft assessment from England’s National Institute for Health and Care Excellence (NICE) has been published,

Read More
07 December 2017

CLINUVEL Newsletter - December 2017

The CLINUVEL team is looking with much optimism and energy to the start of 2018.

Read More
05 December 2017

Lapse and Forfeit of Unlisted Conditional Performance Rights

Lapse and Forfeit of Unlisted Conditional Performance Rights

Read More
05 December 2017

Appendix 3Z - Final Director’s Interest Notice

Final Director’s Interest Notice

Read More

Quick Links